clinical trial · NCT05651828
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute·early phase1·recruiting·n = 34
Advanced Basal Cell CarcinomaVismodegib 150 MG Oral Capsule
brief summary
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
started
Mar 23, 2023
primary completion
Dec 1, 2028
completion
Dec 1, 2029
last updated
Apr 1, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol